These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6794404)

  • 1. [Characterization of FVIII/VW circulating after DDAVP administration (author's transl)].
    Vicente V; Díez LF; Alberca I; San Miguel J; López Borrasca A
    An Esp Pediatr; 1981 Jun; 14(6):436-43. PubMed ID: 6794404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of factor VIII/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VIII).
    Garcia VV; Silva IA; Borrasca AL
    Thromb Haemost; 1982 Aug; 48(1):91-3. PubMed ID: 6813999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities.
    Moffat EH; Giddings JC; Bloom AL
    Br J Haematol; 1984 Aug; 57(4):651-62. PubMed ID: 6430337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP).
    Köhler M; Hellstern P; Miyashita C; von Blohn G; Wenzel E
    Thromb Haemost; 1986 Feb; 55(1):108-11. PubMed ID: 3085261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects.
    Takahashi H; Itoh M; Kobayashi I; Sakuragawa N; Shibata A
    Tohoku J Exp Med; 1980 Oct; 132(2):133-40. PubMed ID: 6777902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Subcutaneous administration of desmopressin to plasma donors: a controlled study].
    Palacios S; Zuazu I; Candela MJ; Rivera J; Vicente V
    Med Clin (Barc); 1995 Oct; 105(14):525-7. PubMed ID: 8523926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
    Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
    Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS
    Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of diabetes regulation on platelet release, fibrinolysis and coagulation tests, before and after stimulation with DDAVP.
    vd Knaap JH; de Boer AC; Pannebakker MA; van Heerde W; den Ottolander GJ
    Thromb Haemost; 1985 Feb; 53(1):118-21. PubMed ID: 3922075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced effect of exercise and DDAVP on factor VIII-von Willebrand Factor and plasminogen activator after sequential application of both the stimuli.
    Vicente V; Alberca I; Mannucci PM
    Thromb Haemost; 1984 Feb; 51(1):129-30. PubMed ID: 6426078
    [No Abstract]   [Full Text] [Related]  

  • 19. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
    Suzuki H; Shima M; Arai M; Kagawa K; Fukutake K; Kamisue S; Nakai H; Morichika S; Tanaka I; Inoue M; Gale K; Tuddenham EG; Yoshioka A
    Thromb Haemost; 1997 May; 77(5):862-7. PubMed ID: 9184393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease.
    Mohri H; Hashimoto Y; Yamazaki E; Kanamori H; Okubo T
    Hematopathol Mol Hematol; 1998; 11(2):109-15. PubMed ID: 9608359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.